Evaluating oxidative stress and inflammation in Gaucher disease
Official title: Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)
Run by University of Minnesota · NCT02437396 · Data updated 2026-11-12
This study is testing how oxidative stress and inflammation affect adults with Gaucher disease type I by looking at blood samples taken over three months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 34 (estimated) |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | October 2015 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT02437396 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with Gaucher disease type I who are stable on specific enzyme replacement therapy or substrate reduction therapy.
✕Probably not a fit
Patients with medically unstable conditions or those who have taken certain antioxidants prior to the study may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess oxidative stress and inflammatory biomarkers in adult patients with Gaucher disease type I. Participants will provide blood samples during three visits over approximately three months, which will be analyzed using standardized immunoassay and LC/MS methods. The study will correlate these biomarkers with currently used diagnostic markers to better understand the disease's impact on oxidative stress and inflammation.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of Gaucher disease and lead to improved diagnostic and therapeutic strategies for patients.
How similar studies have gone: While this approach is focused on Gaucher disease, similar studies evaluating biomarkers in other conditions have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. All participants must be 18 years or older. 2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent. 3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator. 4. GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years). 5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient. 6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study. Exclusion Criteria: 1. Medically unstable conditions in any group as determined by the investigators 2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study. 3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception 4. History of asthma that is presently being treated 5. Subjects who cannot or are unwilling to have blood drawn 6. Unable to adhere to study protocol for whatever reason
Where it's running
-
University of Minnesota
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Reena Kartha, PhD — University of Minnesota
- Study coordinator: Reena Kartha, PhD
- Email: rvkartha@umn.edu
- Phone: 612-626-2436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers
This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.
-
Opioid-Free vs Opioid-Based Anesthesia for Thyroid Surgery
This study tests whether a non-opioid anesthesia approach can match or improve outcomes for adults undergoing thyroidectomy.
-
Training to reduce oxidative stress in knee OA
A six-week program compares supervised knee-strengthening training with a daily 6,000-step walking plan to see if it improves pain, function, and blood markers of cellular stress in people with knee osteoarthritis.
-
Ashwagandha with resistance training to boost strength and stress markers
This 12-week study tests whether taking ASHWAGANDHA along with regular resistance training helps healthy, trained men see improvements in strength, stress levels, sleep, and cognitive function compared with a placebo.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.